Teva: 4th quarter revenue $4.4 billion; up 16% from 2009

By GLOBES
February 8, 2011 10:04




Teva Pharmaceutical Industries Ltd. reported Tuesday that on a non-GAAP (generally accepted accounting principles) basis, it earned $1.1 billion net profit in the fourth quarter of 2010, or $1.25 in earnings per share.

The figure was below the consensus analysts estimate of $1.28 per share.

Teva reported record full year net sales of $16.1 billion for 2010, up 16 percent, compared to 2009.

Fourth quarter revenue was a record $4.4 billion, up 16%, compared to the fourth quarter of 2009.

The pharmaceuticals company reported record global in-market sales of its multiple-sclerosis drug Copaxone of $938 million in the fourth quarter, up 26% compared to the fourth quarter of 2009.

For the full year of 2010, non-GAAP net profit was $4.1 billion ($4.54 per share). Net profit was 36% higher than in 2009, and the EPS figure was 35% higher than in 2009. On a GAAP basis, net profit was $3.3 billion ($3.67 per share).


Related Content

Breaking news
January 23, 2018
N. Ireland militant splinter group says it will end violent campaign

By REUTERS

Israel Weather
  • 9 - 18
    Beer Sheva
    13 - 18
    Tel Aviv - Yafo
  • 8 - 12
    Jerusalem
    11 - 15
    Haifa
  • 12 - 22
    Elat
    12 - 19
    Tiberias